Clinical trial
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With…
NCT00373490 · Merck Sharp & Dohme LLC, Industry · Completed
Key facts
| NCT number | NCT00373490 |
|---|---|
| Title | A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048) |
| Official title | MK0683 Phase1 Clinical Study - Solid Tumor - |
| Lead sponsor | Merck Sharp & Dohme LLC, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Tumors |
| Intervention type | Drug |
| Interventions | Vorinostat |
| Enrollment | 16 |
| Start date | Jul 1, 2006 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Sep 8, 2006 |
| Last update posted | Aug 27, 2015 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: